Advertisement

Latest News

Don't Miss a Beat: MRA Updates at ACC 2026 Scientific Sessions

7 hours ago

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Evolving Research Landscape Drives Progress in CLE at AAD 2026

9 hours ago

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

AMETHYST Phase 3 and Remaining Questions Surrounding Litifilimab in CLE

9 hours ago

Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.

Potential of Targeting BDCA2 in Cutaneous Lupus Erythematosus Management

9 hours ago

Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.

Navigating Multidisciplinary Care for CLE in an Evolving Landscape

10 hours ago

Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.

Advertisement
Advertisement